Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Department of Medicine D, Meir Medical Center, Kfar Saba, Israel.
Shafik
S
Khouri
Andy
A
Kotliroff
Michael
M
Lishner
Howard
H
Amital
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000503:physiopathology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate